• Significant advances in anti-infective portfolio development
• Positive preclinical data for RECCE® 327 against antibiotic-resistant pathogens
• Registrational Phase 3 trial for Diabetic Foot Infections underway

Recce Pharmaceuticals Ltd reported significant advances in the development of its anti-infective portfolio during the half-year ended 31 December 2025. Key highlights included a research abstract and poster presentation at the 2025 Military Health System Research Symposium, demonstrating activity of RECCE® 327 against multiple high-priority bioterrorism pathogens. The company also reported statistically significant positive efficacy data against two clinically significant antibiotic-resistant pathogens, Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa), in rat infection models. Additionally, patient dosing was underway for the Registrational Phase 3 clinical trial for Diabetic Foot Infections (DFI) in Indonesia, with the company expecting to meet a highly statistically significant positive endpoint after dosing approximately 155 patients. The company also announced the passing of its founder and the inventor of Recce's technology platform, Dr Graham JH Melrose, and reported further positive preclinical data from an ongoing research program conducted by Murdoch Children's Research Institute. The Hong Kong Special Administrative Region also formally granted Patent Family 4 for Recce's Anti-Infectives, expiring in 2041. The company received an Advanced Overseas Finding for up to A$85 million for Synthetic Antibiotic Research & Development expenditure from the Department of Industry, Science and Resources.

The company expects to receive a cash inflow of approximately $3.6M in April 2026, representing the final portion of the company's total FY25 R&D tax rebate of $8.9M, of which $5.3M has already been received. This inflow, together with other fundraising activities, will support the company's ongoing operations.